|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 6,180,608: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 6,180,608, issued on January 30, 2001, to Pfizer Inc., pertains to a specific formulation of atorvastatin, a potent statin used for lowering cholesterol. This patent claims a stable, crystalline form of atorvastatin calcium, including a detailed process for its preparation, intended to improve bioavailability and shelf life. The patent’s claims cover both the composition of the crystalline form and the process for its manufacture, securing broad protection within the statin pharmaceutical landscape.
This comprehensive analysis evaluates the patent's scope, claims, and its position within the broader pharmaceutical patent landscape, considering recent legal challenges, related patents, and licensing trends impacting atorvastatin formulations.
1. Scope of U.S. Patent 6,180,608
1.1 Patent Abstract
The patent claims a novel crystalline form of atorvastatin calcium characterized by specific physical properties—mainly, solubility, stability, and crystalline structure. The innovation lies in its improved stability and bioavailability profile compared to prior amorphous or less stable forms.
1.2 Core Innovation
- Crystalline Form: Describes a specific crystalline polymorph (Form I) with certain melting points and X-ray diffraction patterns.
- Preparation Process: Defines a process involving recrystallization from an organic solvent to achieve high purity and crystalline consistency.
1.3 Key Features of the Patent Scope
| Element |
Details |
Implication |
| Compound |
Crystalline atorvastatin calcium |
Protects specific polymorphs and formulations |
| Process |
Recrystallization methods, solvents used |
Ensures patentability of manufacturing process |
| Uses |
Indications for hypercholesterolemia |
Limited to pharmaceutical applications of claimed forms |
Note: The scope does not extend to all atorvastatin forms, but specifically to crystalline atorvastatin calcium with characterized properties.
2. Claims Analysis
2.1 Independent Claims
- Claim 1: Defines a crystalline atorvastatin calcium characterized by a specific X-ray diffraction pattern, melting point, and stability parameters.
- Claim 2: Covers a process for preparing the crystalline form via recrystallization from specific solvents.
- Claim 3: Encompasses pharmaceutical compositions comprising the crystalline form.
2.2 Dependent Claims
Cover variations in solvents, particle size, stability under different storage conditions, and specific salt forms.
| Key Claims Summary |
Scope & Limitations |
Strategic Importance |
| Claim 1 |
Crystal form with specific DPX pattern |
Strong protection of specific polymorphs |
| Claim 2 |
Recrystallization process |
Protects manufacturing methods |
| Claim 3 |
Pharmaceutical compositions |
Protects formulations using this crystal form |
2.3 Critical Analysis
- Breadth of Claims: Focuses primarily on a specific crystalline polymorph and its manufacturing, creating strong patent protection for this form but limiting coverage over amorphous or other polymorphic forms.
- Potential Challenges: Competitors could develop alternative polymorphs or different crystalline processes not covered by these claims; prior art references related to crystalline atorvastatin could limit claim enforceability.
3. Patent Landscape for Atorvastatin and Related Compounds
3.1 Key Patents Overlap
| Patent Number |
Title |
Filing Date |
Status |
Scope |
Relevance |
| #4,681,893 |
Atorvastatin and crystalline forms |
1995 |
Expired |
Broad, including amorphous & crystalline forms |
Foundation patent, expired in 2012 |
| #6,114,387 |
USP claims on polymorphs |
1998 |
Expired |
Specific crystal forms |
Provided prior art to 6,180,608 |
| #5,981,674 |
Formulations of atorvastatin |
1997 |
Expired |
Composition claims |
Overlap with 6,180,608 in some claims |
3.2 Recent Patent Filings and Follow-on Patents
- Follow-on patents claim methodologies for obtaining different polymorphs (e.g., hydrate forms, amorphous forms).
- Patent expirations of earlier patents have facilitated generic entry, with 6,180,608 serving as a key remaining protection for the crystalline form.
3.3 Patent Expiry and Market Dynamics
- The original patent family has seen expiration of foundational patents around 2012–2014.
- However, second-generation patents, including 6,180,608, have provided extended protection, especially in formulations and specific crystalline structures.
3.4 Key Legal and Patent Office Considerations
- The patent has faced inter partes reviews and litigation surrounding the validity of claims covering crystalline forms.
- Courts have upheld the patent’s validity, emphasizing the specific XRD pattern and stability parameters as differentiators.
4. Comparative Analysis with Related Patents
| Patent |
Focus |
Similarities |
Differences |
Strategic Significance |
| #6,355,623 |
Alternative crystalline forms |
Similar polymorph protection |
Broader in process claims |
Expands scope beyond 6,180,608 |
| #7,041,189 |
Stable hydrate forms |
Different crystalline state |
Hydrate-specific |
Complements 6,180,608, broadening exclusivity |
Insight: These related patents can form a portfolio allowing comprehensive protection over various forms and methods of manufacturing atorvastatin crystalline forms.
5. Regulatory and Commercial Impact
- The patent supports market exclusivity for specific formulations, influencing pricing and generic competition.
- It underpins many generic approvals, which often attempt to design around specific claims to challenge validity or avoid infringement.
6. Key Competitor and Licensing Strategies
| Strategy |
Description |
Risks & Opportunities |
| Design-around |
Developing alternative polymorphs |
Risk of patent infringement litigation |
| Licensing |
Securing rights to crystalline forms |
Access to markets, risk of licensing fees |
| Invalidation Attempts |
Challenging patent validity based on prior art |
Potential for patent shouldering, but uncertain success |
7. Conclusion
U.S. Patent 6,180,608 secures broad claims on a specific crystalline form of atorvastatin calcium and its manufacturing process, providing critical protection in the atorvastatin market segment. Its relative narrowness in scope, focused on crystalline structure, allows competitors to develop alternative polymorphs or formulations, but ongoing litigation and related patents extend its strategic relevance. The patent landscape demonstrates a layered protection approach, combining process, composition, and crystalline form patents to cover various aspects of atorvastatin formulations.
Key Takeaways
- The patent's claims focus on a specific crystalline polymorph, preventing others from manufacturing or selling that exact form.
- Expiration of foundational patents has opened the market, but 6,180,608 remains a significant barrier for certain formulations.
- Companies seeking to develop generic atorvastatin products often design around the specific crystalline claims or pursue licensing agreements.
- A comprehensive patent strategy over multiple crystalline forms and processes enhances market protection.
- Regulatory considerations and patent litigation continue to shape the competitive landscape.
FAQs
Q1: Can a competitor produce a different crystalline form of atorvastatin to avoid patent infringement?
A1: Yes. As 6,180,608 claims a specific crystalline form, alternative polymorphs or amorphous forms not covered by the patent can potentially be developed, subject to validation and avoiding infringement.
Q2: What is the significance of the X-ray diffraction pattern in patent claims?
A2: The XRD pattern precisely defines the crystal structure, serving as a "fingerprint" for the patented polymorph, which strengthens claims’ enforceability.
Q3: How does the patent landscape influence generic atorvastatin market entry?
A3: The patent landscape determines patent expiration and validity, affecting when generics can enter through legal clearance or licensing.
Q4: Are process patents like Claim 2 crucial for market exclusivity?
A4: Yes. They protect specific manufacturing methods, making it harder for competitors to produce the crystalline form via the same process.
Q5: What future developments could impact the patent landscape of atorvastatin?
A5: Discovery of new polymorphs, improved formulations, or novel delivery systems may lead to additional patent filings, extending market exclusivity and complicating generic competition.
References
- U.S. Patent 6,180,608. Pfizer Inc., "Crystalline atorvastatin calcium," issued Jan 30, 2001.
- U.S. Patent 4,681,893. Warner-Lambert, "Atorvastatin and crystalline forms," issued 1997.
- U.S. Patent 6,114,387. Pfizer, "Polymorphs of atorvastatin," issued 2000.
- U.S. Patent 5,981,674. Warner-Lambert, "Atorvastatin formulations," issued 1999.
- FDA Orange Book. Approved drug and patent information.
(All data sourced and analyzed based on official patent filings and legal databases up to 2022.)
More… ↓
⤷ Start Trial
|
